The relevance of complement to virus biology

Virology

Volumn 319, Issue 2, 2004, Pages 176-184

  Blue, Clare E ^a   Spiller, O Brad ^b   Blackbourn, David J ^a,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DRUG CARRIER;

ANTIGEN ANTIBODY COMPLEX; BIOLOGY; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; CYTOMEGALOVIRUS; GENE THERAPY; HOST CELL; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HYPOCOMPLEMENTEMIA; INFLAMMATION; MULTIPLE ORGAN FAILURE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; REGULATORY MECHANISM; RETROVIRUS; SEQUENCE HOMOLOGY; SHORT SURVEY; VIRUS INFECTION;

ADENOVIRIDAE; CYTOMEGALOVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 1342279570     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2003.11.029     Document Type: Short Survey

References (81)

1. Albrecht J.C., Nicholas J., Cameron K.R., Newman C., Fleckenstein B., Honess R.W. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. Virology. 190(1):1992;527-530.
2. Antonsson A., Johansson P.J. Binding of human and animal immunoglobulins to the IgG Fc receptor induced by human cytomegalovirus. J. Gen. Virol. 82(Pt 5):2001;1137-1145.
3. Bergelson J.M., Chan M., Solomon K.R., St. John N.F., Lin H., Finberg R.W. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc. Natl. Acad. Sci. U.S.A. 91(13):1994;6245-6249.
4. Cardosa M.J., Porterfield J.S., Gordon S. Complement receptor mediates enhanced flavivirus replication in macrophages. J. Exp. Med. 158(1):1983;258-263.
5. Carney D.F., Koski C.L., Shin M.L. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J. Immunol. 134(3):1985;1804-1809.
6. 2+. J. Immunol. 137(1):1986;263-270.
7. Cichon G., Boeckh-Herwig S., Schmidt H.H., Wehnes E., Muller T., Pring-Akerblom P., Burger R. Complement activation by recombinant adenoviruses. Gene Ther. 8(23):2001;1794-1800.
8. Cooper N.R., Jensen F.C., Welsh R.M. Jr., Oldstone M.B. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J. Exp. Med. 144(4):1976;970-984.
9. Da Costa X.J., Brockman M.A., Alicot E., Ma M., Fischer M.B., Zhou X., Knipe D.M., Carroll M.C. Humoral response to herpes simplex virus is complement-dependent. Proc. Natl. Acad. Sci. U.S.A. 96(22):1999;12708-12712.
10. Dowler K.W., Veltri R.W. In vitro neutralization of HSV-2: inhibition by binding of normal IgG and purified Fc to virion Fc receptor (FcR). J. Med. Virol. 13(3):1984;251-259.
11. Ember J.A., Hugli T.E. Complement factors and their receptors. Immunopharmacology. 38(1-2):1997;3-15.
12. Favoreel H.W., Van de Walle G.R., Nauwynck H.J., Pensaert M.B. Virus complement evasion strategies. J. Gen. Virol. 84(Pt 1):2003;1-15.
13. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., Fearon D.T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. U.S.A. 81(14):1984;4510-4514.
14. Fodor W.L., Rollins S.A., Bianco-Caron S., Rother R.P., Guilmette E.R., Burton W.V., Albrecht J.C., Fleckenstein B., Squinto S.P. The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J. Virol. 69(6):1995;3889-3892.
15. Friedman H.M., Cohen G.H., Eisenberg R.J., Seidel C.A., Cines D.B. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature. 309(5969):1984;633-635.
16. Fries L.F., Friedman H.M., Cohen G.H., Eisenberg R.J., Hammer C.H., Frank M.M. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J. Immunol. 137(5):1986;1636-1641.
17. Gaggar A., Shayakhmetov D., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9(11):2003;1408-1412.
18. Green T.D., Newton B.R., Rota P.A., Xu Y., Robinson H.L., Ross T.M. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine. 20(1-2):2001;242-248.
19. Greenstone H.L., Santoro F., Lusso P., Berger E.A. Human herpesvirus 6 and measles virus employ distinct CD46 domains for receptor function. J. Biol. Chem. 277(42):2002;39112-39118.
20. Hannan J., Young K., Szakonyi G., Overduin M.J., Perkins S.J., Chen X., Holers V.M. Structure of complement receptor (CR) 2 and CR2-C3d complexes. Biochem. Soc. Trans. 30(Pt 6):2002;983-989.
21. Hartshorn K.L., Sastry K., White M.R., Anders E.M., Super M., Ezekowitz R.A., Tauber A.I. Human mannose-binding protein functions as an opsonin for influenza A viruses. J. Clin. Invest. 91(4):1993;1414-1420.
22. Hirsch R.L., Griffin D.E., Winkelstein J.A. Host modification of Sindbis virus sialic acid content influences alternative complement pathway activation and virus clearance. J. Immunol. 127(5):1981;1740-1743.
23. Hohler T., Stradmann-Bellinghausen B., Starke R., Sanger R., Victor A., Rittner C., Schneider P.M. C4A deficiency and nonresponse to hepatitis B vaccination. J. Hepatol. 37(3):2002;387-392.
24. Holers V.M. The complement system as a therapeutic target in autoimmunity. Clin. Immunol. 107(3):2003;140-151.
25. Horvat B., Rivailler P., Varior-Krishnan G., Cardoso A., Gerlier D., Rabourdin-Combe C. Transgenic mice expressing human measles virus (MV) receptor CD46 provide cells exhibiting different permissivities to MV infections. J. Virol. 70(10):1996;6673-6681.
26. Hung S.L., Peng C., Kostavasili I., Friedman H.M., Lambris J.D., Eisenberg R.J., Cohen G.H. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology. 203(2):1994;299-312.
27. Ikeda F., Haraguchi Y., Jinno A., Iino Y., Morishita Y., Shiraki H., Hoshino H. Human complement component C1q inhibits the infectivity of cell-free HTLV-I. J. Immunol. 161(10):1998;5712-5719.
28. Isaacs S.N., Kotwal G.J., Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. U.S.A. 89(2):1992;628-632.
29. Kacani L., Banki Z., Zwirner J., Schennach H., Bajtay Z., Erdei A., Stoiber H., Dierich M.P. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J. Immunol. 166(5):2001;3410- 3415.
30. Kapadia S.B., Molina H., van Berkel V., Speck S.H., Virgin H.W.T. Murine gammaherpesvirus 68 encodes a functional regulator of complement activation. J. Virol. 73(9):1999;7658-7670.
31. Kapadia S.B., Levine B., Speck S.H., Virgin H.W.T. Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection. Immunity. 17(2):2002;143-155.
32. Kedzierska K., Azzam R., Ellery P., Mak J., Jaworowski A., Crowe S.M. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J. Clin. Virol. 26(2):2003;247-263.
33. Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol. Immunol. 38(2-3):2001;175-187.
34. Krych-Goldberg M., Atkinson J.P. Structure-function relationships of complement receptor type 1. Immunol. Rev. 180:2001;112-122.
35. Lee S.H., Jung J.U., Means R.E. 'Complementing' viral infection: mechanisms for evading innate immunity. Trends Microbiol. 11(10):2003;449-452.
36. Litwin V., Grose C. Herpesviral Fc receptors and their relationship to the human Fc receptors. Immunol. Res. 11(3-4):1992;226-238.
37. Lubinski J.M., Wang L., Soulika A.M., Burger R., Wetsel R.A., Colten H., Cohen G.H., Eisenberg R.J., Lambris J.D., Friedman H.M. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J. Virol. 72(10):1998;8257-8263.
38. Makrides S.C. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50(1):1998;59-87.
39. Martino T.A., Petric M., Brown M., Aitken K., Gauntt C.J., Richardson C.D., Chow L.H., Liu P.P. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology. 244(2):1998;302-314.
40. McGreal E., Gasque P. Structure-function studies of the receptors for complement C1q. Biochem. Soc. Trans. 30(Pt 6):2002;1010-1014.
41. McKenzie R., Kotwal G.J., Moss B., Hammer C.H., Frank M.M. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166(6):1992;1245-1250.
42. Mochizuki Y., de Ming T., Hayashi T., Itoh M., Hotta H., Homma M. Protection of mice against Sendai virus pneumonia by non-neutralizing anti-F monoclonal antibodies. Microbiol. Immunol. 34(2):1990;171-183.
43. Moir S., Malaspina A., Li Y., Chun T.W., Lowe T., Adelsberger J., Baseler M., Ehler L.A., Liu S., Davey R.T. Jr., Mican J.A., Fauci A.S. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J. Exp. Med. 192(5):2000;637-646.
44. Mold C., Bradt B.M., Nemerow G.R., Cooper N.R. Epstein-Barr virus regulates activation and processing of the third component of complement. J. Exp. Med. 168(3):1988;949-969.
45. Moore M.D., DiScipio R.G., Cooper N.R., Nemerow G.R. Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/ C3dg receptor (CR2). J. Biol. Chem. 264(34):1989;20576-20582.
46. Morgan B.P., Harris C.L. Complement Regulatory Proteins. 1999;Academic Press, London.
47. Mullick J., Bernet J., Singh A.K., Lambris J.D., Sahu A. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins. J. Virol. 77(6):2003;3878-3881.
48. Nomura M., Kurita-Taniguchi M., Kondo K., Inoue N., Matsumoto M., Yamanishi K., Okabe M., Seya T. Mechanism of host cell protection from complement in murine cytomegalovirus (CMV) infection: identification of a CMV-responsive element in the CD46 promoter region. Eur. J. Immunol. 32(10):2002;2954-2964.
49. Powell R.M., Ward T., Goodfellow I., Almond J.W., Evans D.J. Mapping the binding domains on decay accelerating factor (DAF) for haemagglutinating enteroviruses: implications for the evolution of a DAF-binding phenotype. J. Gen. Virol. 80(Pt 12):1999;3145-3152.
50. Rall G.F., Manchester M., Daniels L.R., Callahan E.M., Belman A.R., Oldstone M.B. A transgenic mouse model for measles virus infection of the brain. Proc. Natl. Acad. Sci. U.S.A. 94(9):1997;4659-4663.
51. Robinson W.E. Jr., Kawamura T., Gorny M.K., Lake D., Xu J.Y., Matsumoto Y., Sugano T., Masuho Y., Mitchell W.M., Hersh E.et al. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 87(8):1990;3185-3189.
52. Sahu A., Isaacs S.N., Soulika A.M., Lambris J.D. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J. Immunol. 160(11):1998;5596-5604.
53. Saifuddin M., Landay A.L., Ghassemi M., Patki C., Spear G.T. HTLV-I activates complement leading to increased binding to complement receptor-positive cells. AIDS Res. Hum. Retroviruses. 11(9):1995;1115-1122.
54. Saifuddin M., Hedayati T., Atkinson J.P., Holguin M.H., Parker C.J., Spear G.T. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 78(Pt 8):1997;1907-1911.
55. Schwaeble W., Dahl M.R., Thiel S., Stover C., Jensenius J.C. The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology. 205(4-5):2002;455-466.
56. Scolding N.J., Morgan B.P., Houston W.A., Linington C., Campbell A.K., Compston D.A. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature. 339(6226):1989;620-622.
57. Segerman A., Atkinson J.P., Marttila M., Dennerquist V., Wadell G., Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77(17):2003;9183-9191.
58. Seppanen M., Lokki M.L., Timonen T., Lappalainen M., Jarva H., Jarvinen A., Sarna S., Valtonen V., Meri S. Complement C4 deficiency and HLA homozygosity in patients with frequent intraoral herpes simplex virus type 1 infections. Clin. Infect. Dis. 33(9):2001;1604-1607.
59. Shafren D.R. Viral cell entry induced by cross-linked decay-accelerating factor. J. Virol. 72(11):1998;9407-9412.
60. Smith G.P., Smith R.A. Membrane-targeted complement inhibitors. Mol. Immunol. 38(2-3):2001;249-255.
61. Solder B.M., Schulz T.F., Hengster P., Lower J., Larcher C., Bitterlich G., Kurth R., Wachter H., Dierich M.P. HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol. Lett. 22(2):1989;135-145.
62. Spear G.T., Takefman D.M., Sullivan B.L., Landay A.L., Jennings M.B., Carlson J.R. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus. Virology. 195(2):1993;475-480.
63. Spear G.T., Lurain N.S., Parker C.J., Ghassemi M., Payne G.H., Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J. Immunol. 155(9):1995;4376-4381.
64. Spiller O.B., Morgan B.P. Antibody-independent activation of the classical complement pathway by cytomegalovirus-infected fibroblasts. J. Infect. Dis. 178(6):1998;1597-1603.
65. Spiller O.B., Morgan B.P., Tufaro F., Devine D.V. Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur. J. Immunol. 26(7):1996;1532-1538.
66. Spiller O.B., Goodfellow I.G., Evans D.J., Almond J.W., Morgan B.P. Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF. J. Infect. Dis. 181(1):2000;340-343.
67. Spiller O.B., Blackbourn D.J., Mark L., Proctor D.G., Blom A.M. Functional activity of the complement regulator encoded by Kaposi's sarcoma associated herpesvirus. J. Biol. Chem. 278(11):2003;9283-9289.
68. Spiller O.B., Robinson M., O'Donnell E., Milligan S., Morgan B.P., Davison A.J., Blackbourn D.J. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J. Virol. 77(1):2003;592-599.
69. Stoiber H., Ebenbichler C., Schneider R., Janatova J., Dierich M.P. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS. 9(1):1995;19-26.
70. Stoiber H., Pinter C., Siccardi A.G., Clivio A., Dierich M.P. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J. Exp. Med. 183(1):1996;307-310.
71. Stoiber H., Clivio A., Dierich M.P. Role of complement in HIV infection. Annu. Rev. Immunol. 15:1997;649-674.
72. Sullivan B.L., Takefman D.M., Spear G.T. Complement canHIV-1 plasma virus by a C5-independent mechanism. Virology. 248(2):1998;173-181.
73. Tatsuo H., Ono N., Tanaka K., Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 406(6798):2000;893-897.
74. Thielens N.M., Tacnet-Delorme P., Arlaud G.J. Interaction of C1q and mannan-binding lectin with viruses. Immunobiology. 205(4-5):2002;563-574.
75. Tugizov S.M., Berline J.W., Palefsky J.M. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat. Med. 9(3):2003;307-314.
76. Van de Walle G.R., Favoreel H.W., Nauwynck H.J., Pensaert M.B. Antibody-induced internalization of viral glycoproteins and gE-gI Fc receptor activity protect pseudorabies virus-infected monocytes from efficient complement-mediated lysis. J. Gen. Virol. 84(Pt 4):2003;939-948.
77. Vasantha S., Coelingh K.L., Murphy B.R., Dourmashkin R.R., Hammer C.H., Frank M.M., Fries L.F. Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. Virology. 167(2):1988;433-441.
78. Wakimoto H., Johnson P.R., Knipe D.M., Chiocca E.A. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10(11):2003;983-990.
79. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 344(14):2001;1058-1066.
80. Wang F.S. Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J. Gastroenterol. 9(4):2003;641-644.
81. Zarkadis I.K., Mastellos D., Lambris J.D. Phylogenetic aspects of the complement system. Dev. Comp. Immunol. 25(8-9):2001;745-762.